Identification of key genes related to cancer associated fibroblasts in neuroblastoma: A comprehensive bioinformatics approach

神经母细胞瘤中与癌症相关的成纤维细胞关键基因的鉴定:一种综合生物信息学方法

阅读:1

Abstract

BackgroundNeuroblastoma (NB) is one of the most common and aggressive pediatric solid tumors, characterized by a highly complex pathogenesis. Within the tumor microenvironment (TME), cancer-associated fibroblasts (CAFs) constitute a major cell population and play a pivotal role in facilitating communication among various stromal cells. However, the specific functions and contributions of CAFs in NB remain incompletely understood.ObjectiveTo investigate the impact of CAFs-related genes on the prognosis of NB, we developed a risk model to facilitate the diagnosis and prognostication of patients.MethodsIn this study, a CAFs gene prognostic model for NB was established using single-cell analysis and genomic sequencing data. The effectiveness of this prognostic model was subsequently evaluated through the development of a nomogram, immune infiltration analysis, drug prediction, and gene set enrichment analysis. Ultimately, the expression levels of the identified key genes were experimentally validated in NB tissues.ResultsA novel prognostic model for CAFs related to NB prognosis was established through single-cell analysis and transcriptome dataset analysis. The prognosis of the high-risk group was worse than that of the low-risk group. The validity of the model was confirmed by nomogram, drug sensitivity analysis, and immune infiltration methods. Finally, the high expression of the key gene STEAP2 in NB tissues was verified by experiments.ConclusionsThe study introduces a new predictive model that uses CAF markers to forecast the prognosis of NB. STEAP2 plays a key role in identifying high-risk neuroblastoma and may become a potential therapeutic target for NB.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。